Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial

Stereotactic ablative radiotherapy (SABR) is a standard-of-care for medically-inoperable-early-stage non-small cell lung cancer (NSCLC). One third of patients progress and chemotherapy is rarely used in this population. We questioned if addition of the immune-checkpoint-inhibitor (ICI) atezolizumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Monjazeb, Arta M., Daly, Megan E., Luxardi, Guillaume, Maverakis, Emanual, Merleev, Alexander A., Marusina, Alina I., Borowsky, Alexander, Mirhadi, Amin, Shiao, Stephen L., Beckett, Laurel, Chen, Shuai, Eastham, David, Li, Tianhong, Vick, Logan V., McGee, Heather M., Lara, Frances, Garcia, Leslie, Morris, Leigh Anne, Canter, Robert J., Riess, Jonathan W., Schalper, Kurt A., Murphy, William J., Kelly, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474145/
https://www.ncbi.nlm.nih.gov/pubmed/37658083
http://dx.doi.org/10.1038/s41467-023-40813-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474145/
https://www.ncbi.nlm.nih.gov/pubmed/37658083
http://dx.doi.org/10.1038/s41467-023-40813-w

Ejemplares similares